Lavipharm
Lavipharm is a pharmaceutical company with a rich legacy in advancing patient care through pioneering healthcare solutions. Globally recognized for its expertise in the development and manufacturing of Transdermal Drug Delivery Systems (TDDSs), the company has established, through its products, a robust presence in major markets around the world, offering patients access to innovative life-improving treatments.
Since 1911, Lavipharm has a long and successful history of commercial operations in the local prescription medicines and OTC markets. Today, it offers a wide range of highest-quality pharmaceutical products in 4 major therapeutic areas: Cardiometabolic, Urology, Central Nervous System and Oncology/Pain. Furthermore, Lavipharm’s OTC product portfolio includes well-known and long-trusted brands, primarily in the area of antiseptics and analgesics. In 2024, the company entered into the emerging market of pharmaceutical cannabis and CBD food supplements in Greece.
Listed on the Athens Exchange since 1995, its stock (ΛΑΒΙ) is included in the FTSE/XA MID CAP, ATHEX ESG and FTSE Russell Indexes.
Cooperations:
Allertec, Alliud Pharma, Alloga, Angelini, Aristo, Asacpharma, Biogaran, Bruno, CA Papaellinas, Centrum, Chiesi, Eurogenerici, Famar, Ferrer, Galenica, Galenicum, Gebro, Henning Arzneimittel, Hormosan, Insu America, Lirimed, Mundipharma, Neopharma, Neuraxpharm, Paladin, Pharmabart, Pharmbio, PS Marketing, Resund Pharma, Sandoz, Sunny Pharmaceutical, Technomede, Teva, Tikun, Vereinsfield, Zentiva, 2care4
CONTACT
Address: Agias Marinas Street, P.O.Box 59, GR 19002 Peania
- Telephone:+30 210 6691 000
- Website: https://www.lavipharm.com
- Email: [email protected]